Aadi Bioscience (AADI) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Aadi Bioscience (AADIResearch Report) today and set a price target of $48.00. The company’s shares closed last Monday at $15.36, close to its 52-week low of $11.00.

According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -26.1% and a 22.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aadi Bioscience with a $39.00 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $49.80 and a one-year low of $11.00. Currently, Aadi Bioscience has an average volume of 101.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.

Read More on AADI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed